Letter to the editor: Use Intractable nausea and vomiting successfully related with granisetron 5-hydroxtrytamine type 3 receptor antagonists in Palliative Medicine
Available accessOtherFirst published online December, 2007
Letter to the editor: Use Intractable nausea and vomiting successfully related with granisetron 5-hydroxtrytamine type 3 receptor antagonists in Palliative Medicine
Tong JGSelective Serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNSDrugs2005; 19: 225—38 .
2.
Currow DC , Coughlan M. , Fardell B. , Cooney NJUse of ondansetron in palliative medicine . J Pain Symptom Manag1997; 13(5): 302—7 .
3.
Cole RM , Robinson F. , Harvey L. , Trethowan K. , Murdoch V.Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer . J Pain Symptom Manag1994; 9(1): 48—50 .
4.
Corrigan BW , Nicholls B. , Thakrar B. , Lam R. , Grosse C. , Alianti J. et al. Heterogeneity in systemic availability of ondansetron and granisetron following oral administration . Drug Metab Dispos1999; 27(1): 110—2 .
5.
Kaiser R. , Sezer O. , Papies A. , Bauer S. , Schelenz C. , Tremblay P-B. et al. Patient-tailored antiemetic treatment with 5-Hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes . J Clin Oncol2002; 20(12): 2805—11 .
6.
Dickman A. , Schneider J. , Varga J.The Syringe Driver, Continuous subcutaneous infusions in palliative care. Second edition. Oxford University Press , 2005.
